Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in... by Colombo GL, Valentino MC, Fabi A, Dieci MV, Caruggi M, Bruno GM, Lombardi G, Di Matteo S

Connect to this object online.

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study by Lazzaro C, Bordonaro R, Cognetti F, Fabi A, De Placido S, Arpino G, Marchetti P, Botticelli A, Pronzato P, Martelli E

Connect to this object online.

Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients by Fabi A, Giannarelli D, Malaguti P, Ferretti G, Vari S, Papaldo P, Nisticò C, Caterino M, De Vita R, Mottolese M, Iacorossi L, Cognetti F

Connect to this object online.